29TH EAHP CONGRESS
12-13-14 MARCH
PERSON CENTRED PHARMACY - NAVIGATING DIGITAL HEALTH

Abstract number: 5PSQ-032

EFFECTIVENESS AND SAFETY IN THE USE OF SOFOSBUBIR/VELPATASVIR IN THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION

L. RUBIO ORTOLÁ, M.J. COMPANY ALBIR, E. VICENTE ESCRIG, A. MARTÍNEZ LLIBERATO, T. CEBOLLA BELTRÁN, A. PUPLÁ BARTOLL, M.D. BELLÉS MEDALL, R. FERRANDO PIQUERES

Hospital General Universitario de Castellón. Hospital Pharmacy. Castellón, Spain. rubio_lucort@gva.es

BACKGROUND & IMPORTANCE

Hepatitis C virus (HCV) causes chronic infection in 55-85% of patients, increases the risk of liver cirrhosis to 15-30% in 20 years and is the main cause of hepatocellular carcinoma (70-80%) in Spain.

AIM & OBJECTIVES

To evaluate the effectiveness, safety and drug interaction profile of sofosbuvir/velpatasvir in patients with chronic HCV.

MATERIALS AND METHODS

Observational and retrospective study. Jan 2019 - Jul 2023

Included: all HCV patients treated with sofosbuvir/velpatasvir.

Variables:

- Sex and age at baseline.
- Baseline: viral load (VL) at baseline (VL0), HCV genotype, degree of fibrosis, co-infection with Human Immunodeficiency Virus (HIV).
- Treatments: previous treatments, combination with ribavirin and potential drug interactions with concomitant treatment.
- Results: VL at the end of treatment (VLend) and at 12 and 24 weeks after completion (VL12 and VL24), sustained viral response (SVR) was defined as undetectable VL12/VL24 (SVR12/SVR24).
- Adverse reactions (ARs) reported by patients.

RESULTS

- 80 patients, 70.0% (N=56) were men.
- Median age: 53,8 years (IQR:49,0-58,8).
- 10,0%(N=8) of patients have received interferon or interferon+ribavirin.
- 8,8%(N=7) had HIV coinfection.
- The association with ribavirin was used in 7,5% of patients (N=6).
- SVR12 was achieved in 96,7% of patients (N=58) and all mantain response an SVR24.
- 36,3%(N=29) of patients were identified with potential drug interactions and 37,5%(N=30) of patients reported AR.









CONCLUSION AND RELEVANCE

- Sofosvubir/velpatasvir is an effective and safe therapy for the treatment of HCV infection.
- The potential drug-drug interactions of DAAs highlight the importance of pharmaceutical care in this group of patients